Combined Topical Corticosteroid and Topical Cyclosporine-A 0.05% for Management of COVID-19 Keratoconjunctivitis: A pilot study. | ||||
| Egyptian Journal of Ophthalmology, (Mansoura Ophthalmic Center) | ||||
| Article 2, Volume 1, Issue 4, December 2021, Page 189-197 PDF (802.94 K) | ||||
| Document Type: Original Articles | ||||
| DOI: 10.21608/ejomos.2021.96897.1033 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Sherein Mahmoud Hagras   1; Mona Abdelhamid Nassief2; Ameera Gamal Abdelhameed3; Omar Khaled Alduwailah4
| ||||
| 1ophthalmology; faculty of medicine; Mansoura university; Mansoura; Egypt | ||||
| 2ophthalmology department, Tanta University, Faculty of medicine | ||||
| 3ophthalmology department, Mansoura University, Faculty of Medicine, Mansoura, Egypt | ||||
| 4ophthalmology department, Farwanyiah Hospital, Kuwait. | ||||
| Abstract | ||||
| Purpose To evaluate the effectiveness and safety of combined use of topical corticosteroids and topical Cyclosporine-A 0.05% in the treatment of COVID-19 acute Keratoconjunctivitis. Study design: A pilot study. Methods Twelve patients (13 eyes) with COVID-19 acute Keratoconjunctivitis received topical 1% prednisolone acetate 4 times daily, 0.05% cyclosporine-A 4 times daily together with non-preserved artificial tears. Symptoms and signs were recorded before and after treatment. Results Seven females and 5 males with a mean age of 42.5 ± 10.89 years (range 23-61 years) were included. Baseline examination of all patients revealed variable degrees of eyelid swelling, conjunctival hyperemia and follicular conjunctivitis. Keratitis had a characteristic pattern of small (˂1mm), gray-white marginal subepithelial infiltrates raising the overlying epithelium without associated epithelial defect. They were separated from the limbus by about 1 mm of clear space and in some cases; they extended for 12 o’clock hours circumlimbal. With treatment, patients reported rapid improvement of symptoms with a mean duration of 3.25 ± 1.6 days (range 1-6 days). At the 7th day of treatment, all signs disappeared in all patients, except for patient number 5, who had persistent mild conjunctival hyperemia and SEI which resolved completely by the 10th day of treatment. No recurrence of SEI was noted after 3 weeks. No ocular side effects of prednisolone acetate or cyclosporine-A were noted in any patient. Conclusion Combined topical 1% prednisolone acetate and 0.05% cyclosporine-A appears to be effective, and safe in the treatment of COVID-19 Keratoconjunctivitis. | ||||
| Keywords | ||||
| Covid-19; keratoconjunctivitis; restasis | ||||
|
Statistics Article View: 250 PDF Download: 267 |
||||
